Aclarion Inc. (ACON) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for ACON, including 3 press releases and news items and 1 SEC filing. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Revenue, TTM
- $98.6K
- Revenue growth
- +46.0%
- Net income, TTM
- -$10.11M
- Net margin
- -10260.0%
- Cash
- $14.19M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks380%
2026-05-172026-11-08
Mix1490d
- Other7(50%)
- Insider6(43%)
- SEC Filings1(7%)
Activity · 52 weeks7554 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Aclarion Inc.10-Q - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsStudy conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with discographyAuthors conclude Nociscan "may, in time, replace provocative lumbar discography" in appropriately selected patientsBolsters the case for physician adoption and payor support for Nociscan BROOMFIELD, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmente
- PRAclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 202685% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitmentOverall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end$14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial BROOMFIELD, Colo., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc
- PRAclarion to Present at the 20th Annual LD Micro Main EventBROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ:ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday, October 20, 2026 at 11:30 AM PT. Brent Ness, Chief Executive Officer will represent the company. Presentation Details Event: LD Micro Main Event XXDate: Tuesday, October 20, 2026Time: 11:30 AMLocation: Luxe Sunset Boulevard Hotel, Los Angeles, CaliforniaWebcast: https://ldmicroevents.com/ To register for the event, please contact: registration@ldmicro.com About the LD Micro Main Event XX The
- PRAclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentNew criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and expected timing of the initial readout from its pivotal CLARITY clinical trial. Based on
- PRAclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven SitesNYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intellig
- PRAclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial SiteUniversity of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovationTen sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technolo
- INSIDERDirector Williams Amanda M bought $15,990 worth of shares (5,857 units at $2.73), increasing direct ownership by 29% to 25,857 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERCFO Gould Gregory A bought $24,500 worth of shares (10,000 units at $2.45), increasing direct ownership by 20% to 60,000 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Executive Officer Ness Brent bought $12,091 worth of shares (5,234 units at $2.31), increasing direct ownership by 5% to 111,534 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Bond Ryan bought $50,059 worth of shares (21,122 units at $2.37), increasing direct ownership by 38% to 76,122 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Wesemann William bought $5,031 worth of shares (2,150 units at $2.34), increasing direct ownership by 10% to 23,713 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Neal David K bought $18,000 worth of shares (7,500 units at $2.40), increasing direct ownership by 33% to 30,002 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- PRAclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan ProcessPatent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflowDesigned to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centersExtends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help ph
- SECSEC Form 10-Q filed by Aclarion Inc.10-Q - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the TechnologyPartnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networksGoodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical researchAvailability of Nociscan in Indiana reflects Company’s focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, toda
- PRAclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S.Continued progress toward the CLARITY trial readout with the addition of multiple new trial sitesStrengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwideStrong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)),
- PRAclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical PracticeAbstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablationEarly findings from real-world evidence study demonstrate immense utility and ability of Nociscan to be incorporated into clinical practiceCase study represents first reported use of Nociscan to guide basivertebral nerve ablation in a patient without classic Modic changes on standard MRI, resulting in 95% relief of long-standing chronic low back pain BROOMFIELD, Colo., July 21, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and propri
- SECSEC Form S-8 filed by Aclarion Inc.S-8 - Aclarion, Inc. (0001635077) (Filer)
- PRAclarion Announces Texas Spine Care Center as New CLARITY SiteTexas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatmentCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., July 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algori
- INSIDERChief Strategy Officer Bond Ryan was granted 55,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERExecutive Chairman Thramann Jeffrey John was granted 100,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERChief Financial Officer Gould Gregory A was granted 50,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Sequira Amanda Mae was granted 20,000 shares (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
- INSIDERDirector Breidbart Scott was granted 20,000 shares, increasing direct ownership by 353% to 25,664 units (SEC Form 4)4 - Aclarion, Inc. (0001635077) (Issuer)
ACON FAQ
10 questionsWhat does Aclarion Inc. do?
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.What is the latest news on ACON?
In the last 30 days Quantisnow tracked 4 wire items for ACON: 3 press releases and news items and 1 SEC filing. The most recent was published on November 5, 2026.What is ACON revenue?
Aclarion Inc. (ACON) reported $98.6K of revenue for the twelve months ended Sep 30, 2026. That is up 46.0% from the year before. Revenue for fiscal 2025 was $75.7K.Is ACON profitable?
No. Aclarion Inc. reported a net loss of $10.11M for the twelve months ended Sep 30, 2026.How much cash and debt does ACON have?
Aclarion Inc. reported $14.19M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ACON stock trade?
Aclarion Inc. (ACON) is listed on NASDAQ.What sector and industry is ACON in?
Aclarion Inc. operates in the Health Care sector, Medical Specialities industry.When did Aclarion Inc. go public?
Aclarion Inc. (ACON) completed its IPO in 2022.What companies are similar to ACON?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.), NTRA (Natera Inc.). Compare ACON side-by-side with any of them on Quantisnow.How can I track ACON on Quantisnow?
Quantisnow aggregates Aclarion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACON to receive live email and push alerts on every new disclosure.